In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1.1% to 8,873 points.
Four ASX shares that have failed to follow the market higher today are listed below. Here’s why they are falling:
Brainchip Holdings Ltd (ASX: BRN)
The Brainchip share price is down 2% to 15.2 cents. This semiconductor company’s shares have been under heavy selling pressure since the release of another disappointing quarterly update. Despite entering the commercialisation stage a few years ago, Brainchip revealed cash receipts of just US$0.4 million for the three months ended 31 December. Given that its market capitalisation is still $350 million, it wouldn’t be surprising if the selling continues if there’s no meaningful improvement in its sales.
Credit Corp Group Ltd (ASX: CCP)
The Credit Corp share price is down over 15% to $12.07. Investors have been selling this debt collector’s shares following the release of its half-year results. Credit Corp posted a 4% increase in revenue to $283.6 million and flat net profit after tax of $44.1 million. Looking ahead, management believes it can still achieve its net profit after tax guidance range of $100 million to $110 million. Investors don’t appear confident it will get there.
Graincorp Ltd (ASX: GNC)
The Graincorp share price is down 3% to $6.00. This may have been driven by a broker note out of Macquarie Group Ltd (ASX: MQG). This morning, the broker downgraded the grain exporter’s shares to a neutral rating (from outperform) with a reduced price target of $6.60 (from $8.30). Macquarie appears concerned that margins could remain under pressure in the near term, which could weigh on its earnings growth.
Neuren Pharmaceuticals Ltd (ASX: NEU)
The Neuren Pharmaceuticals share price is down 12% to $14.25. This morning, Neuren Pharmaceuticals revealed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative trend vote on its marketing authorisation application for trofinetide in the European market. Neuren’s CEO, Jon Pilcher, commented: “Given the totality of experience with trofinetide in clinical trials and real world use over many years, this negative trend vote is frustrating for us and the Rett syndrome community in the EU. We fully support Acadia’s intention to seek re-examination of the CHMP opinion in February, if necessary.”
The post Why Brainchip, Credit Corp, Graincorp, and Neuren shares are falling today appeared first on The Motley Fool Australia.
Should you invest $1,000 in BrainChip Holdings Limited right now?
Before you buy BrainChip Holdings Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and BrainChip Holdings Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 Jan 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Credit Corp share price crashes 14% following H1 FY26 result
- Guess which ASX 200 healthcare share is crashing 22% on Tuesday on European blow
- Top broker weighs in after Graincorp shares plummet 14%
- Why Appen, Brightstar, Graincorp, and Northern Star shares are sinking today
- GrainCorp shares slide nearly 15%. Is this ASX 200 stock now oversold?
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.